HIV myths vs facts — what the evidence actually says.

Every myth on this page showed up for a reason. HIV myths almost always do a job: they draw a line between "people like me" and "people who get HIV," and that line feels protective. Naming that a myth protects the person holding it is different from mocking them for holding it.

This page corrects 20 myths — 14 that circulated for decades and six newer ones surfacing in 2024–2026 discourse — sourced from CDC, NIH/NIAID, DHHS, WHO, UNAIDS, and the peer-reviewed trials that settled these questions. Nothing here is opinion; every claim carries a citation you can check.

Why myths persist — and why correcting one is care, not a correction of character

Stigma is a private bargain people make with themselves. If HIV only happens to "other people" — different identities, worse judgment — believing that keeps a person feeling safe. Myths persist because they push risk and blame onto someone else so the myth-holder doesn't have to sit with uncertainty about their own body, family, or past choices.

That's also why shaming someone for repeating a myth rarely works. A person who hears "that's stupid, everyone knows that" learns to stop asking questions out loud — not to stop believing the myth. CDC and UNAIDS guidance on stigma reduction is explicit that language and framing shape whether people come forward for testing, disclose to partners, or stay in care.3

None of that means facts don't matter. HIV criminalization laws, workplace discrimination, and family estrangement are downstream of exactly these myths, and the stakes for people living with HIV are real. This page holds both things at once: the science isn't up for debate, and the person asking an outdated question is usually not an enemy — often they're afraid, under-informed, or repeating something they were taught decades ago.

U=U is based on the principle that all people with HIV have a right to accurate and meaningful information about their social, sexual, and reproductive health based on science, not stigma. — Bruce Richman, founder, Prevention Access Campaign (U=U)2

Transmission myths

"You can get HIV from casual contact, toilets, or sharing food."

Myth: Hugging, shaking hands, sharing dishes, using the same toilet seat, or sitting near someone living with HIV can pass the virus.

Fact: HIV is fragile outside the human body and does not survive well on surfaces or in air.1 CDC's transmission guidance is specific about the mechanism: HIV is transmitted through certain body fluids — blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk — from a person with HIV, and those fluids need a route into another person's bloodstream, typically through mucous membranes, open cuts or sores, or direct injection.1 Casual, everyday contact does not create that route. Saliva, tears, and sweat aren't on CDC's list of fluids that transmit HIV, and there's no documented case of transmission through sharing a meal, a toilet, or a handshake. This myth persists partly because 1980s fear campaigns taught a generation to associate proximity itself with danger — an association that outlived the facts that disproved it.

"Mosquitoes transmit HIV."

Myth: Because mosquitoes transmit malaria and West Nile virus by biting multiple people, they must be able to transmit HIV the same way.

Fact: They can't, and the biology explains why. HIV does not replicate inside insects, and a mosquito does not inject blood from a previous person into the next person it bites — it injects its own saliva, not prior blood.1 Malaria and viruses like West Nile actually reproduce inside the mosquito and travel to its salivary glands; HIV has no such life cycle in an insect host. Decades of surveillance in regions with heavy mosquito exposure and high HIV prevalence — sub-Saharan Africa foremost — have never turned up a case linked to insect bites.1 This myth tends to surface from a reasonable but incorrect analogy.

"Kissing transmits HIV."

Myth: Any kissing — closed-mouth or open-mouth — carries meaningful HIV risk.

Fact: Closed-mouth kissing carries no risk.1 Open-mouth kissing is listed by CDC as carrying no to negligible risk, because saliva does not transmit HIV; the only theoretical scenario involves both partners having bleeding gums or mouth sores with blood present, and even then no confirmed case has been well documented.1 Kissing someone living with HIV, including deep kissing, is not a transmission event to be anxious about.

"PrEP or U=U doesn't really prevent transmission."

Myth: Antiretroviral-based prevention — treatment as prevention, or PrEP — sounds too good to be true, so surely it doesn't hold up outside a lab.

Fact: This is among the most rigorously tested claims in modern medicine. HPTN 052 followed 1,763 serodiscordant couples across nine countries and found a 93% lower risk of genetically linked transmission with early ART, with zero linked transmissions when the partner living with HIV was durably suppressed.2 PARTNER2 followed 782 gay male couples through more than 76,000 acts of condomless sex with a suppressed partner and recorded zero linked transmissions.4 Opposites Attract, in Australia, Brazil, and Thailand, followed 343 couples through 16,800 condomless anal sex acts, same result: zero.5

PrEP has an equally strong record. HPTN 083 found long-acting injectable cabotegravir reduced HIV risk 66% versus daily oral PrEP in cisgender men and transgender women who have sex with men.6 HPTN 084 found the same injectable reduced risk 88% in cisgender women in sub-Saharan Africa.7 Five major trials, one consistent finding: treatment-based and PrEP-based prevention work dramatically.

Treatment myths

"ART is toxic — worse than the virus itself."

Myth: ART causes more organ damage than living with untreated HIV, so people are better off avoiding it.

Fact: This myth has real roots — early-1990s antiretrovirals did carry significant toxicity. But the modern evidence runs the opposite direction, decisively. The START trial randomized 4,685 adults with high CD4 counts (above 500 cells/mm³, no medical urgency by older standards) to immediate versus deferred ART and found a 57% lower rate of serious AIDS- and non-AIDS-related events in the immediate group, including fewer cardiovascular events, cancers, and infections — not more.8 The trial's monitoring board stopped it early because the benefit was so clear it became unethical to keep the comparison group waiting.8 The companion TEMPRANO trial in Côte d'Ivoire found similarly that earlier ART plus preventive TB therapy reduced severe illness and death.8 Modern regimens are also simply different drugs than those that earned ART its 1990s reputation — most people today take one pill, once a day, with far milder side effects.9

"Natural remedies work just as well."

Myth: Herbal supplements, unregulated "immune boosters," or alternative regimens can manage HIV without pharmaceutical treatment.

Fact: No herbal or supplement regimen has been shown in controlled trials to suppress HIV viral load, and unsupervised use carries real harm. Many botanicals interact with antiretroviral metabolism through the same liver enzyme pathways (particularly CYP3A4) that process ART, lowering drug levels enough to allow rebound and resistance, or raising them enough to cause toxicity.9 St. John's Wort is the best-documented example: it induces CYP3A4 and significantly reduces blood levels of protease inhibitors, risking treatment failure.9 This isn't a reason to shame someone reaching for a supplement — the evidence-based response is to bring the full supplement list to an HIV provider, not hide it.

"I don't need meds if I feel fine."

Myth: Feeling healthy is a reliable sign that HIV isn't progressing, so treatment can wait until symptoms appear.

Fact: CD4 decline during untreated HIV is often silent for years — moderate decline typically produces no symptoms at all.8 START specifically enrolled people who felt healthy, with CD4 counts still above 500, and found that waiting for symptoms or lower counts before starting treatment produced significantly worse outcomes.8 Feeling fine is genuinely good news, but it isn't a lab result, and isn't a substitute for one.

"Once I'm undetectable, I can stop my meds."

Myth: Reaching undetectable means the virus is gone or under permanent control, so treatment can be paused.

Fact: Undetectable doesn't mean cured. HIV persists in a latent reservoir that ART doesn't clear, and stopping treatment allows rebound, usually within two to four weeks.10 The SMART trial tested exactly this: interrupting treatment versus continuous treatment. It stopped early because the interruption group had significantly more disease progression and death, including more cardiovascular, kidney, and liver events.10 SPARTAC, which tested time-limited early treatment during acute infection, found some delay in progression but not durable control — most viral loads rebounded and required treatment to resume.10 "Undetectable" is the result of ongoing treatment, not proof it's no longer needed.

U=U-specific myths

"U=U only works if you're perfect about your meds."

Myth: Any missed dose or imperfect adherence means U=U protection disappears.

Fact: The definition of U=U the major trials tested was sustained viral suppression — generally a viral load below 200 copies/mL, maintained for six months or more — not flawless daily perfection.2 Doses get missed occasionally without necessarily causing detectable rebound, because modern regimens have real pharmacological forgiveness. What matters is the sustained lab result, tracked with a provider, not a private anxiety spiral over one missed pill.

"U=U doesn't apply to anal sex."

Myth: The zero-transmission findings only apply to vaginal sex, and anal sex — often assumed riskier — falls outside U=U's protection.

Fact: This is backward from how the evidence developed. PARTNER2 and Opposites Attract were both designed specifically to test U=U in gay male couples having condomless anal sex, because clinicians recognized it needed its own dedicated evidence rather than assumptions from heterosexual data.45 Both found zero linked transmissions when the HIV-positive partner was suppressed, across tens of thousands of condomless anal sex acts combined.45 U=U's evidence base for anal sex is, if anything, more extensive than for any other sex act.

"U=U doesn't apply to breastfeeding."

Myth: Even with an undetectable viral load, breastfeeding always carries meaningful HIV transmission risk to an infant, so it should never be attempted.

Fact: This is genuinely more complicated than U=U for sex, and guidance has changed. Without maternal ART or infant prophylaxis, breastfeeding transmission risk is 15–20% over two years — real and serious.11 But the 2023 DHHS Perinatal HIV Guidelines update reflects newer evidence: for a person with a consistently suppressed viral load through pregnancy and postpartum, breastfeeding transmission risk drops below 1% — low, but not zero.11 Because it isn't zero the way sexual U=U is, guidelines shifted from a blanket recommendation against breastfeeding to shared decision-making: virally suppressed parents can choose to breastfeed, formula-feed, or use donor milk, with close monitoring, and it's explicitly inappropriate to involve child protective services in that decision.11

PrEP myths

"PrEP is just for gay men."

Myth: PrEP mainly benefits men who have sex with men, so it isn't really relevant to women, transgender people, or heterosexual couples.

Fact: CDC guidance is explicit that PrEP is recommended for anyone at ongoing risk of HIV exposure, regardless of gender or orientation — cisgender women, transgender people, people who inject drugs, and people in serodifferent relationships.12 HPTN 084, which found long-acting cabotegravir reduced HIV risk 88% versus daily oral PrEP, enrolled exclusively cisgender women in sub-Saharan Africa, run because women had been underrepresented in earlier PrEP research.7 The perception that PrEP is a "gay men's drug" is itself a stigma artifact from early marketing that has measurably slowed uptake among women and heterosexual men who could benefit.

"PrEP causes bone loss and kidney failure."

Myth: Taking PrEP long-term will meaningfully damage your bones and kidneys.

Fact: Real but modest effects exist, and framing matters. Tenofovir-based PrEP is associated with small, generally reversible decreases in bone mineral density and small increases in creatinine reflecting reduced kidney filtration in some users, which is why routine eGFR monitoring is part of standard PrEP care.12 These changes typically aren't clinically significant for healthy adults, and alternatives exist for people with pre-existing kidney or bone risk.6 "Real risk exists and is monitored" is different from "PrEP will damage your organs" — conflating the two keeps people who'd benefit away out of disproportionate fear.

"PrEP means condoms are useless."

Myth: Once someone starts PrEP, condoms serve no further purpose.

Fact: PrEP is highly effective at preventing HIV specifically, but CDC is explicit it doesn't prevent other STIs or pregnancy.12 Condoms remain meaningful protection against gonorrhea, chlamydia, syphilis, and pregnancy regardless of PrEP use. PrEP is an HIV-specific tool that pairs with, not replaces, other sexual health practices.

"Only rich people can get PrEP."

Myth: PrEP is prohibitively expensive and effectively unavailable without significant income or excellent insurance.

Fact: This tracks a real cost barrier that used to be larger, but coverage pathways exist that many people don't know about. Under the ACA, PrEP is a preventive service most private plans must cover without cost-sharing, a mandate that survived the 2024 Braidwood v. Becerra litigation largely intact.12 For people without insurance, state AIDS Drug Assistance Programs continue providing access in every state, even after the federal Ready, Set, PrEP program wound down in 2025.12 Cost is a real worry — the honest fact is "harder than it should be," not "impossible."

Cure myths

"There's a cure being hidden from the public."

Myth: Pharmaceutical companies or governments are suppressing a real cure for HIV to protect ongoing treatment revenue.

Fact: The actual state of cure science is publicly documented and far less dramatic than a hidden cure — but genuinely remarkable. Roughly a dozen and a half people worldwide have achieved sustained HIV remission after stopping ART, each following a stem-cell transplant for blood cancer using donor cells carrying a rare mutation (CCR5-delta-32) resistant to most HIV strains.13 NIAID's own cure research program is explicit this approach isn't scalable — it's only justified when someone already needs a transplant for cancer.13 Research into broader strategies — gene editing, latency-reversal, broadly neutralizing antibodies — is active, publicly funded, and published openly, not hidden.13 This myth tends to reflect justified frustration that a cure doesn't exist yet.

"AIDS drugs just make Big Pharma rich."

Myth: Antiretroviral pricing exists purely to enrich pharmaceutical companies, with no real cost basis or benefit to patients.

Fact: This deserves a nuanced answer, because pricing critique and access-expansion progress are both true. U.S. list prices for branded antiretrovirals are genuinely high, and patents limit generic competition for newer drugs.14 At the same time, global access has expanded dramatically through voluntary licensing and PEPFAR-funded procurement, a major reason ART reached roughly 30.7 million people worldwide by the latest UNAIDS count.14 Both are documented; treating drug companies as purely villainous or purely benevolent flattens a complicated picture.

"The virus was engineered — HIV isn't real, or isn't what they say it is."

Myth: HIV was created in a lab, or doesn't actually cause AIDS, or the entire epidemic has been misrepresented.

Fact: HIV/AIDS denialism has a specific, documented history, most associated with biologist Peter Duesberg, who argued in the late 1980s and 1990s that HIV doesn't cause AIDS — a position rejected by essentially the entire scientific community. When adopted as governmental policy, most consequentially in South Africa under President Thabo Mbeki, 2000–2005, the cost was hundreds of thousands of preventable deaths from delayed ART rollout, per peer-reviewed analysis.15 On origins: phylogenetic analysis of the HIV-1 genome traces the pandemic strain to a single cross-species transmission from chimpanzees in central Africa in the early 20th century, with no genetic evidence for lab origin.15 Denialism isn't a harmless alternative opinion — it's a position with a body count when adopted at scale.

Stigma and identity myths

"HIV is a gay disease."

Myth: HIV is fundamentally tied to gay male identity or behavior, and framing it otherwise is political correctness rather than epidemiology.

Fact: Global epidemiology has never supported this framing, even though the U.S. epidemic's early visibility centered gay and bisexual men. Worldwide, women and girls account for roughly 46% of new HIV infections per the latest UNAIDS Global AIDS Update, with sub-Saharan Africa's burden driven overwhelmingly by heterosexual transmission and structural factors like gender-based violence, not identity.14 Treating HIV as belonging to one identity group stigmatizes that group unfairly and falsely reassures everyone else they have nothing to consider.

"You can tell someone has HIV by looking at them."

Myth: People living with HIV look visibly sick, thin, or otherwise identifiable.

Fact: The vast majority of people living with HIV on effective treatment are asymptomatic and indistinguishable from anyone else — that's the point of modern treatment working. The dramatic wasting associated with untreated late-stage AIDS in the 1980s and 1990s reflected the absence of effective therapy then, not what HIV inherently looks like.9 Testing, not appearance, is the only reliable way to know anyone's status, including your own.

"Only certain 'kinds' of people get HIV."

Myth: HIV risk is a function of identity or category — gay, a drug user, a sex worker — rather than specific exposures.

Fact: Public health researchers have moved deliberately away from "risk group" language toward "risk behavior" and structural-driver language, because the data supports it. What predicts HIV acquisition is specific exposure — condomless sex with a partner of unknown status, shared injection equipment, and, upstream, conditions like lack of testing access and healthcare discrimination.3 Category-based thinking is stigmatizing and epidemiologically wrong: the actual determinant is behavior and access, not identity.

"People with HIV can't have kids, relationships, or careers."

Myth: An HIV diagnosis effectively ends parenthood, partnership, or professional life.

Fact: All three are demonstrably untrue at population scale. With ART started early and maintained through pregnancy, mother-to-child transmission risk falls under 1–2%, and serodifferent couples routinely conceive safely when the partner living with HIV is durably suppressed, consistent with U=U evidence covered earlier.112 On employment, the ADA protects people living with HIV from workplace discrimination — status alone isn't grounds for termination or refusal to hire.16 Real discrimination in dating, hiring, and family court still happens, but these are legal and social failures to correct, not medical limitations.

New myths surfacing in 2024–2026 discourse

Myths evolve with the news cycle. These six are showing up in comment sections, group chats, and clinic waiting rooms now, and deserve the same evidence-based treatment as the older ones.

"The cuts to PEPFAR and Ryan White are exaggerated — nobody's really losing care."

Myth: Reporting on 2025 federal HIV funding cuts is overstated advocacy messaging, not a reflection of real impact.

Fact: The 2025 funding volatility was real and independently modeled, even though the final outcome shifted through the year. A 2025 modeling study projected that a 90-day PEPFAR funding freeze would cause an estimated 60,000 to 74,000 excess HIV deaths across seven high-burden African countries.17 Domestically, advocacy organizations tracked a proposed House FY2026 bill that would have cut domestic HIV funding by more than $1.7 billion, including a 20% cut to Ryan White.17 That proposal didn't become law — a February 2026 bipartisan agreement preserved funding at FY2025 levels — but a better-than-feared outcome doesn't mean the disruption clinics and patients felt was manufactured.17

"Long-acting injectables are only for people who can't handle daily pills."

Myth: Long-acting injectables exist mainly as a fallback for people who are "non-adherent" with daily medication.

Fact: This gets the clinical reality backward and imports outdated "compliance" language guidelines have moved away from. Long-acting options — Cabenuva for treatment, Apretude or twice-yearly lenacapavir for prevention — are chosen for reasons unrelated to adherence difficulty: privacy, preference for less frequent dosing, or wanting fewer daily reminders of a diagnosis.6 Framing injectables as a fallback for "difficult" patients stigmatizes both those who choose them and the shift toward patient-centered choice.

"Doxy-PEP will just create antibiotic-resistant superbugs and cancel out any STI benefit."

Myth: Doxy-PEP for bacterial STI prevention is reckless because it will inevitably drive resistance severe enough to negate any benefit.

Fact: The resistance concern is legitimate and taken seriously in CDC's own guidance — not a myth to dismiss, but currently overstated relative to the evidence. CDC's 2024 clinical guidelines, based on three large randomized trials, found 200 mg of doxycycline within 72 hours after sex reduced syphilis and chlamydia by more than 70% and gonorrhea by roughly 50% in men who have sex with men and transgender women with a bacterial STI in the past 12 months.18 Guidance requires ongoing STI testing every three to six months and doesn't recommend doxy-PEP universally — only for the population the trials studied.18

"GLP-1 drugs cure HIV-associated weight gain."

Myth: Semaglutide and similar GLP-1 drugs (Ozempic, Wegovy) fully resolve HIV-associated lipohypertrophy.

Fact: There's genuine randomized-trial evidence of benefit — but "cure" overstates it. A phase 2b placebo-controlled trial of once-weekly semaglutide in 108 people living with HIV with lipohypertrophy (abnormal fat accumulation, a known complication of HIV and some antiretrovirals) found significant reductions in visceral fat at 32 weeks versus placebo.19 That's meaningful, but not a cure: the underlying cause isn't reversed, only partially treated. GLP-1s are a promising add-on, not a fix.

"You can DIY-test and fully diagnose yourself with a home HIV test."

Myth: A single at-home HIV self-test result — positive or negative — is a complete, standalone diagnosis.

Fact: Self-tests are a genuinely valuable, CDC-endorsed tool for expanding access, but they're a screening step, not a final diagnosis. CDC notes oral-swab self-tests have lower sensitivity for recent infection, particularly during PrEP use, and mail-in kits are processed by a lab rather than read at home.20 Any reactive result requires confirmatory lab testing, since rapid tests carry a window period where recent infection may not yet be detectable.20 Self-testing is real progress — not a full diagnostic pathway alone.

"HIV originated because of immigrants, or specifically came from Haiti."

Myth: HIV entered the United States because of Haitian immigrants, framing an entire nationality as an origin point or vector of blame.

Fact: This myth has a long, damaging history — Haitians were formally classified as a CDC "risk group" in the early 1980s, a designation removed after advocacy made clear it stigmatized an entire nationality rather than describing an actual epidemiological pattern.15 Genomic evidence reconstructed by Michael Worobey and colleagues from archived 1970s blood samples traces a dispassionate chain: HIV-1 subtype B likely moved from Central Africa to the Caribbean around the 1960s, then into the U.S. around 1970, with New York City as the key hub — a decade before AIDS was first recognized in 1981.15 That research also formally exonerated Gaétan Dugas, long mischaracterized as "Patient Zero": the data found no evidence he was the primary U.S. case.15 The pandemic's origin is settled viral genetics — not a story about which group to blame.

How to respond when someone tells you a myth

Knowing the facts is only half of this. The other half is what to actually say — to a family member, a coworker, or a nurse at urgent care — without turning the conversation into a fight or a lecture. A few principles make this easier, then some scripts.

Principles before scripts

• Assume good faith first. Most people repeating a myth learned it somewhere — an old health class, a scared relative, outdated news — and aren't trying to cause harm.
• Correct the claim, not the person. "That's actually outdated — here's what current research shows" lands differently than "how do you not know that."
• You don't owe anyone your status to correct a myth. You can say "that's not accurate" without disclosing that you're living with HIV.
• One conversation rarely undoes decades of messaging. Planting a seed of doubt is a success, even without an instant reversal.
• Know when to disengage. If someone responds with hostility, you're allowed to end the conversation. Correcting a myth is not a debate you're required to win.

Script: a family member says something outdated

"I know that used to be what people thought, but the science has moved a lot. HIV can't spread through [casual contact / sharing food / hugging] — that's been well established for decades by the CDC. I get why it's scary to think about, but you don't need to worry about that with me."

Script: a friend repeats a stigmatizing stereotype

"I've actually looked into this — HIV doesn't work like a 'certain kind of person' thing. Globally it's almost evenly split by gender, and in the U.S. it shows up across every group. It's about specific situations and access to healthcare, not about who someone is."

Script: a coworker makes an assumption at work

"Just so you know, HIV isn't something that spreads through everyday contact at work — sharing a break room, a phone, a keyboard, none of that is a risk. The ADA actually protects people living with HIV from exactly this kind of assumption affecting how they're treated at work."

Script: a provider or clinician says something outdated

"I want to flag that some of what you just said doesn't match current CDC and DHHS guidance — for example, on [breastfeeding / U=U / treatment interruption]. Can we look at the most recent guidelines together?" Providers are not immune to outdated training, and you're allowed to ask for a second opinion or a referral to an HIV specialist if a provider seems unfamiliar with current standards.

For more on navigating disclosure conversations specifically, see our companion pieces on disclosure and stigma and the language we use, and for the emotional weight of repeated stigma exposure, shame and stigma in HIV care.

Florida-specific myths

Some myths take a sharper, more consequential form in Florida.

"Florida's HIV disclosure and exposure laws just reflect basic safety."

Myth: Florida's HIV-specific criminal statutes exist because HIV exposure is uniquely dangerous, and the law simply reflects that danger.

Fact: Florida is one of many U.S. states with HIV-specific criminal statutes that predate the modern understanding of U=U, and advocacy organizations have documented that these laws often apply regardless of actual transmission risk or viral suppression status — a person who is undetectable, and who the science says cannot transmit HIV, can still face enhanced criminal liability solely because of their HIV status.16 The CDC has noted that HIV criminalization laws are not evidence-based as prevention tools, and the Center for HIV Law and Policy has documented that they instead discourage testing and disclosure, since a diagnosis creates new legal exposure a person didn't have before testing.16 For a full breakdown, see our companion piece on HIV criminalization in Florida.

"A 'clean' test result means someone is safe to be with."

Myth: Describing an STI or HIV test result as "clean" is a harmless, common way to talk about testing negative.

Fact: "Clean" as a description of test status is common in dating culture, including in Florida's dating scenes, but it directly implies that a positive result — and by extension, a person living with HIV — is "dirty." That framing is a small, constant reinforcement of exactly the stigma this article works against, showing up in contexts like dating apps where people may not stop to think about the implication. UNAIDS guidance specifically flags "clean" versus "dirty" framing around HIV status as stigmatizing and recommends neutral language instead — "tested negative" or "undetectable," not "clean."3 Word choice in casual conversation is one of the more fixable contributors to stigma, because it doesn't require legislation — just noticing the habit.